San Francisco, CA, United States
San Francisco, CA, United States

Time filter

Source Type

Patent
Vaxart Inc. | Date: 2016-12-28

Provided herein are compositions and methods for generating an immunogenic response in humans. Such compositions include an immunogenic biological agent encompassed by (ii) an agent that directs delivery of the immunogenic biological agent to the ileum of the human, wherein agent (ii) is an enteric coating (e.g., Eudragit) that has a threshold pH 5.8-6.8. Further provided are methods for designing such compositions, e.g., for vaccines.


News Article | May 3, 2017
Site: marketersmedia.com

Wiseguyreports.Com Adds “Oral Vaccines -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database This report studies Oral Vaccines in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering By types, the market can be split into By Application, the market can be split into Polio Rabies Rotavirus Cholera HIV Respiratory Infections Influenza Tuberculosis Others By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India Global Oral Vaccines Market Professional Survey Report 2017 1 Industry Overview of Oral Vaccines 1.1 Definition and Specifications of Oral Vaccines 1.1.1 Definition of Oral Vaccines 1.1.2 Specifications of Oral Vaccines 1.2 Classification of Oral Vaccines 1.2.1 Live Attenuated Vaccines 1.2.2 Killed/Inactivated Vaccines 1.2.3 Recombinant Vaccines 1.2.4 Others 1.3 Applications of Oral Vaccines 1.3.1 Polio 1.3.2 Rabies 1.3.3 Rotavirus 1.3.4 Cholera 1.3.5 HIV 1.3.6 Respiratory Infections 1.3.7 Influenza 1.3.8 Tuberculosis 1.3.9 Others 1.4 Market Segment by Regions 1.4.1 North America 1.4.2 China 1.4.3 Europe 1.4.4 Southeast Asia 1.4.5 Japan 1.4.6 India 8 Major Manufacturers Analysis of Oral Vaccines 8.1 GlaxoSmithKline Plc. 8.1.1 Company Profile 8.1.2 Product Picture and Specifications 8.1.2.1 Product A 8.1.2.2 Product B 8.1.3 GlaxoSmithKline Plc. 2016 Oral Vaccines Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.1.4 GlaxoSmithKline Plc. 2016 Oral Vaccines Business Region Distribution Analysis 8.2 PaxVax Corporation 8.2.1 Company Profile 8.2.2 Product Picture and Specifications 8.2.2.1 Product A 8.2.2.2 Product B 8.2.3 PaxVax Corporation 2016 Oral Vaccines Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.2.4 PaxVax Corporation 2016 Oral Vaccines Business Region Distribution Analysis 8.3 Merial, Inc. 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.2.1 Product A 8.3.2.2 Product B 8.3.3 Merial, Inc. 2016 Oral Vaccines Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.3.4 Merial, Inc. 2016 Oral Vaccines Business Region Distribution Analysis 8.4 Merck Sharp & Dohme Corp 8.4.1 Company Profile 8.4.2 Product Picture and Specifications 8.4.2.1 Product A 8.4.2.2 Product B 8.4.3 Merck Sharp & Dohme Corp 2016 Oral Vaccines Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.4.4 Merck Sharp & Dohme Corp 2016 Oral Vaccines Business Region Distribution Analysis 8.5 VALNEVA Canada Inc. 8.5.1 Company Profile 8.5.2 Product Picture and Specifications 8.5.2.1 Product A 8.5.2.2 Product B 8.5.3 VALNEVA Canada Inc. 2016 Oral Vaccines Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.5.4 VALNEVA Canada Inc. 2016 Oral Vaccines Business Region Distribution Analysis 8.6 QUíMICA SUIZA S.A 8.6.1 Company Profile 8.6.2 Product Picture and Specifications 8.6.2.1 Product A 8.6.2.2 Product B 8.6.3 QUíMICA SUIZA S.A 2016 Oral Vaccines Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.6.4 QUíMICA SUIZA S.A 2016 Oral Vaccines Business Region Distribution Analysis 8.7 Immunitor, Inc 8.7.1 Company Profile 8.7.2 Product Picture and Specifications 8.7.2.1 Product A 8.7.2.2 Product B 8.7.3 Immunitor, Inc 2016 Oral Vaccines Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.7.4 Immunitor, Inc 2016 Oral Vaccines Business Region Distribution Analysis 8.8 Aventis (Sanofi S.A.) 8.8.1 Company Profile 8.8.2 Product Picture and Specifications 8.8.2.1 Product A 8.8.2.2 Product B 8.8.3 Aventis (Sanofi S.A.) 2016 Oral Vaccines Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.8.4 Aventis (Sanofi S.A.) 2016 Oral Vaccines Business Region Distribution Analysis 8.9 Serum Institute of India Pvt. Ltd 8.9.1 Company Profile 8.9.2 Product Picture and Specifications 8.9.2.1 Product A 8.9.2.2 Product B 8.9.3 Serum Institute of India Pvt. Ltd 2016 Oral Vaccines Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.9.4 Serum Institute of India Pvt. Ltd 2016 Oral Vaccines Business Region Distribution Analysis 8.10 Swiss Serum and Vaccine Institute Berne 8.10.1 Company Profile 8.10.2 Product Picture and Specifications 8.10.2.1 Product A 8.10.2.2 Product B 8.10.3 Swiss Serum and Vaccine Institute Berne 2016 Oral Vaccines Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.10.4 Swiss Serum and Vaccine Institute Berne 2016 Oral Vaccines Business Region Distribution Analysis 8.11 Bull Bio - NCIPD Ltd. 8.12 Vaxart, Inc. 8.13 Shantha Biotechnics 8.14 Crucell (Janssen Global Services, LLC) For more information, please visit https://www.wiseguyreports.com/sample-request/1240272-global-oral-vaccines-market-professional-survey-report-2017


News Article | June 5, 2017
Site: www.businesswire.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today it will present at the Jefferies 2017 Healthcare Conference in New York City. Wouter Latour, M.D., chief executive officer, will be presenting on Wednesday, June 7, 2017 at 11:30 a.m., Eastern Standard Time. The presentation will cover Vaxart’s proprietary oral vaccine platform and latest developments on its tablet vaccine candidates for infectious diseases and immuno-oncology indications. Samir Singh, senior vice president of Corporate Development & Strategy, will be attending the conference as well. Vaxart will be hosting one-on-one investor meetings at the conference. Please contact Isabel Zakoscielny at Jefferies to schedule an investor meeting with the company. Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. Its lead development programs are oral tablet vaccines for seasonal influenza, norovirus, respiratory syncytial virus (RSV) and immuno-oncology indications. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration, and eliminate the risk of needle-stick injury and medical waste associated with injectable vaccines. For more information, please visit www.vaxart.com.


Patent
Vaxart Inc. | Date: 2015-02-20

Provided herein are compositions and methods for generating an immunogenic response in humans. Such compositions include an immunogenic biological agent encompassed by (ii) an agent that directs delivery of the immunogenic biological agent to the ileum of the human, wherein agent (ii) is an enteric coating (e.g., Eudragit) that has a threshold pH 5.8-6.8. Further provided are methods for designing such compositions, e.g., for vaccines.


News Article | February 15, 2017
Site: www.businesswire.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that its norovirus tablet vaccine met the primary and secondary endpoints for safety and immunogenicity in a Phase 1 clinical trial. “The norovirus Phase 1 results are an important milestone for our oral vaccine platform as well as for the entire vaccine space,” said Dave Liebowitz, MD, PhD, chief medical officer of Vaxart. “Building on results from previous studies, the tablet vaccine platform has been well tolerated across multiple indications, and we consistently see robust and broad responses for our candidate vaccines. The norovirus results are particularly striking as they were obtained with a single dose of our tablet vaccine.” The norovirus tablet vaccine was well tolerated in all subjects. Solicited symptoms and unsolicited adverse events were mostly mild in severity with no serious adverse events (SAEs) reported in the study to date. The vaccine also met its immunogenicity endpoint in both dose groups, as measured by a significant increase in the norovirus blocking antibody titers (BT ) in serum. Significant mucosal immune responses were observed as well, and the vaccine generated potent gut homing, memory, and plasmablast B cell activation. “The norovirus tablet vaccine combines ease of oral delivery with a novel mode of immunization that induces both a local intestinal immune response as well as a systemic antibody response. As a result, the norovirus tablet vaccine generates rapid, robust intestinal immune responses against norovirus,” said Sean Tucker, PhD, chief scientific officer of Vaxart. “We believe that the generation of a potent immune response at the same site as the actual norovirus infection will serve as an effective first line of defense, and may provide better cross protection against divergent strains than serum antibody responses alone.” The randomized, double-blind, placebo-controlled Phase 1 dose-ranging study assessed the safety and immunogenicity of Vaxart’s norovirus (GI.1, Norwalk) tablet vaccine in 66 healthy adult volunteers, with 46 of the subjects immunized with a single dose of the oral tablet vaccine at two different dose levels and 20 subjects given placebo tablets. Norovirus is recognized as a leading cause of acute gastroenteritis. It is a common intestinal infection that typically lasts three to five days and is marked by watery diarrhea, vomiting, abdominal cramps, nausea and sometimes fever. Symptoms can be more severe in older adults and young children and may lead to serious complications including death. Norovirus causes frequent and widespread outbreaks in the military, food industry, travel industry, child care facilities, elderly homes and healthcare facilities. The U.S. Centers for Disease Control and Prevention (CDC) estimates that norovirus causes 19 to 21 million illnesses in the United States each year, resulting in 56,000 to 71,000 hospitalizations and 570 to 800 deaths. In a recent John Hopkins University study, researchers estimated healthcare costs of norovirus at $4.2 billion and lost productivity costs at $56.2 billion globally. Currently there are no norovirus vaccines approved by the U.S. Food and Drug Administration. For further information on norovirus, its burden on human health and vaccine development, please visit the websites of the CDC http://www.cdc.gov/norovirus/ and the Public Library of Science http://collections.plos.org/norovirus. Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. Its lead development programs are oral tablet vaccines designed to protect against Norovirus, seasonal influenza and respiratory syncytial virus (RSV). Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration, and eliminate the risk of needle-stick injury and medical waste associated with injectable vaccines. For more information, please visit www.vaxart.com.


Patent
Vaxart Inc. | Date: 2012-06-25

The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.


Patent
Vaxart Inc. | Date: 2010-11-12

The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.


Patent
Vaxart Inc. | Date: 2010-09-15

The invention provides chimeric viral expression vectors and method of use for providing an immune response against H1N1 influenza. The compositions of the invention can be used as vaccines for H1N1 strains. Advantages include rapid development and availability once a strain is isolated, and effective oral or mucosal administration.


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, a privately held, clinical-stage company developing recombinant vaccines that are administered by tablet rather than by injection, today announced that Vaxart founder and chief scientific officer Sean Tucker, PhD, presented pre-clinical data from its Ebola vaccine program at the Modern Vaccines Adjuvants & Delivery Systems MVADS 2015 in Leiden, NL. Dr. Tucker discussed the data in his presentation, “Clinical development of an oral vaccine to prevent Ebola virus infection,” on Monday, May 18, 2015. Vaxart is a privately held, clinical-stage company developing tablet vaccines. The company’s proprietary delivery platform is suitable to deliver any recombinant vaccine in oral form and allows rapid development to address emerging threats. Vaxart vaccines can be conveniently self-administered, with no cold chain distribution requirements and no medical waste. For more information, please visit www.vaxart.com.


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc., a privately held, clinical-stage company developing vaccines that are administered by tablet rather than by injection, today announced that Vaxart Founder and Chief Scientific Officer Dr. Sean Tucker, PhD, will present clinical data from its seasonal flu vaccine program at the upcoming Society for Mucosal Immunology Conference in Berlin. Dr. Tucker will present the data in his presentation “Mucosal Immune Responses Following Radio Controlled Capsule Delivery to Human Intestines: An Open Label Clinical Trial of an Influenza Vaccine Based on Recombinant Adenovirus” on Friday, July 17, 2015. Vaxart is a privately held, clinical-stage company developing a broad range of vaccines based on its proprietary oral recombinant vaccines platform. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration, are easy to administer, and eliminate medical waste and risk of injury associated with injectable vaccines. For more information, please visit www.vaxart.com.

Loading Vaxart Inc. collaborators
Loading Vaxart Inc. collaborators